Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
Aims The GLP1 agonist lixisenatide is glucagonostatic and reduces post‐prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D). <br></br> Methods In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctiv...
Huvudupphovsmän: | Ballav, C, Dhere, A, Kennedy, I, Agbaje, O, Owen, K, White, S, Franklin, R, Hartman, B, Holst, J, Holman, J |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
Wiley
2020
|
Liknande verk
Liknande verk
-
PROLONGED INFUSION OF GLUCAGON-LIKE PEPTIDE-1 IN TYPE-2 DIABETES NORMALIZES INSULIN-RESPONSE TO GLUCOSE
av: Gribble, F, et al.
Publicerad: (1995) -
Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.
av: Zhang, Q, et al.
Publicerad: (2013) -
Glucagon like peptide-1 similarly amplifies insulin secretion in late-onset type 1 and type 2 diabetes
av: Maksoud, H, et al.
Publicerad: (1999) -
Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
av: Kim, A, et al.
Publicerad: (2021) -
Type 1 and type 2 diabetes-chalk and cheese?
av: Owen, K, et al.
Publicerad: (2009)